| Drug Name | Arzerra (Ofatumumab) |
|---|---|
| Drug Class |
Anticancer
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
Safety communication
|
| Specialty (Theraputic area) |
Hematology
Oncology
|
| Risk |
hepatitis B virus reactivation warning Safety update on a fatal infusion reaction reported in a patient with Chronic lymphocytic leukemia (Cll) who was treated with intravenous ofatumumab Risk of Progressive Multifocal Encephalopathy (PML) Following Ofatumumab Use |
| safety communication |
|
| Dear Healthcare provider letter DHPC |
|
